甲磺酸阿帕替尼用药适宜性研究

Research of Rational Use of Apatinib Mesylate

目的对甲磺酸阿帕替尼在临床使用中的用药适宜性进行研究。方法采用回顾性调查方法,通过查阅病历,详细了解患者基本情况、用药信息和不良反应等进行分析研究。结果阿帕替尼主要用在经过至少两种系统化疗失败后的胃腺癌或胃食管结合部腺癌患者,在临床中常用治疗剂量为0.25或0.5 g,低于说明书载明的0.85 g的推荐剂量。结论阿帕替尼主要为晚期胃腺癌或胃/食管结合部腺癌患者三线或三线以上治疗用药,在0.25或0.5 g治疗剂量下表现出较好的耐受性,但在使用过程中应注意使用剂量对治疗结果的影响。

OBJECTIVE To investigate and analyze the rational use of apatinib in cancer hospital. METHODS Retrospective study was applied. Through reviewing medical records, the patient＇s basic information, drug therapy information and adverse drug effects were collected and analyzed. RESULTS Apatinib is mainly used in patients with advanced metastatic gastric or esophagogas- trie junction cancer who have failed at least two chemotherapeutic regimens. The clinical common dose of apatinib was 0. 25 or 0. 5 g, less than the dose of 0. 85 g recommended in drug instruction. CONCLUSION Apatinib is a new choice for gastric or esophagogas- tile junction cancer. It has demonstrated tolerable adverse effects in these patients. However, at present, more attentions should be paid to possible effect of drug dose on clinical outcome.